GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » Total Equity

Vanda Pharmaceuticals (FRA:VM4) Total Equity : €500.5 Mil (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Total Equity?

Vanda Pharmaceuticals's total equity for the quarter that ended in Mar. 2024 was €500.5 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Vanda Pharmaceuticals Total Equity Historical Data

The historical data trend for Vanda Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Total Equity Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 369.85 372.59 446.86 497.68 499.68

Vanda Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 500.38 498.33 508.89 499.68 500.48

Vanda Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Vanda Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=594.619-94.937
=499.7

Vanda Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=600.467-99.992
=500.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals (FRA:VM4) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » Total Equity
Comparable Companies
GLUE STRO EPIX ENTA ACRV XERS CDXC BOLD INO INZY OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
VNDA:USA VM4:Germany
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Website
https://www.vandapharma.com
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals (FRA:VM4) Headlines

No Headlines